AML
Conference Coverage
Kidney function in African American AML patients not linked to reduced survival compared with whites
ORLANDO –
Conference Coverage
Will TP53-mutated AML respond to immunotherapy?
NATIONAL HARBOR, MD. – Patients with TP53-mutated AML were shown to have increased immune infiltration, but it isn’t clear if they will respond...
News
Adverse cytogenetics trump molecular risk in NPM1-mutated AML
The findings have implications for postremission treatment decisions, including whether NPM1-mutated patients should receive allogeneic...
Conference Coverage
For tough AML, half respond to selinexor plus chemotherapy
AMSTERDAM – The addition of selinexor looks promising in relapsed/refractory AML, but Karyopharm Therapeutics will be focusing first on approval...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
News
FDA approves ivosidenib frontline for certain AML patients
The expanded approval means that ivosidenib can be used first-line for acute myeloid leukemia patients with an IDH1 mutation who are not eligible...
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
Pruritus linked to wide variety of cancers
The odds of specific cancers vary by race.